XWELL, Inc. 8K

XWELL, Inc. announced its fiscal 2025 financial results and significant strategic, biosecurity, and financing developments, including a $31.3 million private placement to bolster liquidity and support ongoing initiatives.

On April 1, 2026, XWELL, Inc. reported its fiscal 2025 results, disclosing approximately $29.2 million in revenue, reduced cost of sales and operating expenses versus 2024, and an operating loss of about $15.7 million and net loss of about $17.0 million, alongside operational updates including new wellness retail locations in New York’s Penn Station and Florida, an extended three-year Traveler-based Genomic Surveillance Program with the CDC and Ginkgo Bioworks, a strategic AI biosecurity partnership with PieQ, and a February 26, 2026 at-the-market private placement with American Ventures, LLC generating roughly $31.3 million in gross proceeds to strengthen liquidity and fund note repurchases, preferred stock and warrant redemptions, and general corporate purposes.

Filing Facts

CIK

1410428

Ticker

-

Form

8K

Source Type

fda

Accession

0001104659-26-038550

Alert Tier

7